| 0.5015 -0.002 (-0.3%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.63 | 1-year : | 0.7 |
| Resists | First : | 0.54 | Second : | 0.6 |
| Pivot price | 0.52  |
|||
| Supports | First : | 0.45 | Second : | 0.37 |
| MAs | MA(5) : | 0.51  |
MA(20) : | 0.51 |
| MA(100) : | 0.6 |
MA(250) : | 1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.8 |
D(3) : | 31.7 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 6.5 | Low : | 0.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATYR ] has closed above bottom band by 22.7%. Bollinger Bands are 66.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.53 - 0.53 | 0.53 - 0.54 |
| Low: | 0.49 - 0.5 | 0.5 - 0.5 |
| Close: | 0.5 - 0.5 | 0.5 - 0.51 |
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Wed, 12 Aug 2026
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright - MarketBeat
Sun, 09 Aug 2026
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) Investors - Contact Levi & Korsinsky Before December 8, 2025 - The National Law Review
Fri, 07 Aug 2026
aTyr Pharma Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Thu, 06 Aug 2026
FMR LLC and Abigail Johnson (ATYR) disclose 2.5% ATYR Pharma ownership - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 9.553e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 18,510 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.32e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -33 % |
| Return on Assets (ttm) | 609.4 % |
| Return on Equity (ttm) | -46.6 % |
| Qtrly Rev. Growth | 190000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -203.14 |
| EBITDA (p.s.) | -1.06788e+008 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 8.28e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|